Loading organizations...
§ Private Profile · Beijing, Beijing, China
NGS-based DNA testing for tumors, specializing in precision oncology diagnostics and gene-based treatment guidance for cancer.
Founded in 2016 by Chief Executive Officer Du Bo, GeneCast Biotechnology is a precision medicine and oncology organization based in Taizhou, Jiangsu Province, China, that provides advanced DNA testing for tumors utilizing next-generation sequencing technologies. The enterprise develops commercial diagnostic services and comprehensive NGS tumor profiling products that assist clinicians, cancer patients, and pharmaceutical clients with gene-based guidance for targeted medical treatments. To expand its commercial footprint in precision oncology, the company established a strategic partnership with Cancer Genetics to commercialize specialized tissue-of-origin testing within the Chinese market. The executive leadership team features Chief Scientific Officer Chen Weizhi, whose research portfolio encompasses 38 patents, alongside Executive Vice President Ma Guosheng. Furthermore, the organization recently strengthened its business development operations by recruiting Fanping Wang, who previously served as the head of Illumina China.
GeneCast Biotechnology has raised $42.5M across 1 funding round.
GeneCast Biotechnology has raised $42.5M in total across 1 funding round.
GeneCast Biotechnology has raised $42.5M across 1 funding round. Most recently, it raised $42.5M Series D in October 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 30, 2019 | $42.5M Series D | CICC Capital | — | Announced |
GeneCast Biotechnology has raised $42.5M in total across 1 funding round.
GeneCast Biotechnology's investors include CICC Capital.